John Heyburn

Progesterone Rapidly Decreases Brain Edema: Treatment Delayed up to 24 Hours Is Still Effective

Robin L. Roof, Revital Duvdevani, John Heyburn et al. · Experimental Neurology · 1996 · 246 citations

Hormonal Contraceptive, Hours Is, Neuropharmacology +8

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma

Sandra P. D’Angelo, Omid Hamid, Ahmad A. Tarhini et al. · Investigational New Drugs · 2017 · 27 citations · Full text

Cancer Immunosurveillance, Medicine, Melanoma +8

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Axel Grothey, Jonathan Strosberg, Lindsay A. Renfro et al. · Clinical Cancer Research · 2017 · 26 citations · Full text

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas

Robin L. Jones, Sant P. Chawla, Steven Attia et al. · Cancer · 2019 · 26 citations · Full text

Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial.

Raffit Hassan, Thierry Jahan, Hedy L. Kindler et al. · Journal of Clinical Oncology · 2012 · 12 citations

Neuro-oncology, Medicine, Metronomic Therapy +15